Log In Sign up
The largest database of trusted experimental protocols

Anti human mouse cd44 pe fluor 610

Manufactured by Thermo Fisher Scientific
Visit Supplier
Sourced in United States

The Anti-human/mouse CD44 (PE-Fluor 610) is a fluorescent-labeled antibody that specifically binds to the CD44 cell surface receptor. It can be used for the identification and enumeration of CD44-positive cells in flow cytometry applications.

Automatically generated - may contain errors

Lab products found in correlation

Galios flow cytometer, by Beckman Coulter (5 mentions) Bovine serum albumin (bsa), by Merck Group (5 mentions) Cd16 cd32 mouse fc block, by BD (5 mentions) Kaluza software, by Beckman Coulter (4 mentions) Red blood cell lysis buffer, by Merck Group (3 mentions) Anti human cd24 apc, by Thermo Fisher Scientific (3 mentions) Ethylene diamine tetraacetic acid (edta), by Thermo Fisher Scientific (3 mentions) Collagenase type 1, by Worthington (3 mentions) 0.5m edta, by Thermo Fisher Scientific (1 mentions)

Close spelling variants of this product

Anti-CD44 (63 citations) CD44-PE (44 citations) Anti-CD44-PE (14 citations) Anti-mouse CD44-PE (7 citations) Anti-human/mouse CD44 PE (2 citations) Mouse anti-human CD44 (2 citations)

5 protocols using anti human mouse cd44 pe fluor 610

1

Characterizing Circulating Tumor Cell Phenotypes

Check if the same lab product or an alternative is used in the 5 most similar protocols
To analyze CSC phenotypes, TU-BcX-4IC was enzymatically digested with type I collagenase (Worthington Biochemical Corporation, Lakewood, NJ, USA) at room temperature, neutralized with media, and then filtered. Circulating tumor cells were collected in whole blood with 0.5 M EDTA (Gibco Invitrogen, Carlsbad CA), incubated in red blood cell lysis buffer (0.008% NH4Cl, pH 7.2–7.4; Sigma-Aldrich, St. Louis MO) and washed with PBS. Collected cells from the tumor and blood samples were placed in a staining solution containing 1% Bovine Serum Albumin (BSA; Sigma-Aldrich) and 1% CD16/CD32 Mouse BD Fc Block™ (BD Biosciences) in PBS. The following primary antibodies were used: Anti-human CD24 (APC) and anti-human/mouse CD44 (PE-Fluor 610) purchased from eBiosciences (San Diego, CA, USA). All cells from the blood were analyzed with a Galios Flow Cytometer (Beckman Coulter, Brea, CA, USA) running Kaluza software (Beckman Coulter). At least 5,000 events were analyzed and reported as the mean ± SEM.
Matossian M.D., Chang T., Wright M.K., Burks H.E., Elliott S., Sabol R.A., Wathieu H., Windsor G.O., Alzoubi M.S., King C.T., Bursavich J.B., Ham A.M., Savoie J.J., Nguyen K., Baddoo M., Flemington E., Sirenko O., Cromwell E.F., Hebert K.L., Lau F., Izadpanah R., Brown H., Sinha S., Zabaleta J., Riker A.I., Moroz K., Miele L., Zea A.H., Ochoa A., Bunnell B.A., Collins-Burow B.M., Martin E.C, & Burow M.E. (2021). In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clinical & Translational Oncology, 24(1), 127-144.
+ Open protocol
+ Expand
2

Isolation and Analysis of Circulating Tumor Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Circulating tumor cells were collected in whole blood with 0.5M EDTA (Gibco Invitrogen, Carlsbad CA), incubated in red blood cell lysis buffer (0.008% NH4Cl, pH 7.2–7.4; Sigma-Aldrich, St. Louis MO), and washed with PBS. Collected cells from the tumor and blood samples were placed in staining solution containing 1% Bovine Serum Albumin (BSA; Sigma-Aldrich) and 1% CD16/CD32 Mouse BD Fc BlockTM (BD Biosciences) in PBS. The following primary antibodies were used: Anti-human CD24 (APC), and anti-human/mouse CD44 (PE-Fluor 610) purchased from eBiosciences (San Diego, CA, USA). All cells from the blood were analyzed with a Galios Flow Cytometer (Beckman Coulter, Brea, CA, USA) running Kaluza software (Beckman Coulter). At least 5000 events were analyzed and reported as the mean ± SEM.
Chang T.C., Matossian M.D., Elliott S., Burks H.E., Sabol R.A., Ucar D.A., Wathieu H., Zabaleta J., Valle L.D., Gill S., Martin E., Riker A.I., Miele L., Bunnell B.A., Burow M.E, & Collins-Burow B.M. (2020). Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor. PLoS ONE, 15(10), e0226464.
+ Open protocol
+ Expand
3

Characterizing Circulating Tumor Cell Phenotypes

Check if the same lab product or an alternative is used in the 5 most similar protocols
To analyze CSC phenotypes, TU-BcX-4IC was enzymatically digested with type I collagenase (Worthington Biochemical Corporation, Lakewood, NJ, USA) at room temperature, neutralized with media, and then filtered. Circulating tumor cells were collected in whole blood with 0.5 M EDTA (Gibco Invitrogen, Carlsbad CA), incubated in red blood cell lysis buffer (0.008% NH4Cl, pH 7.2–7.4; Sigma-Aldrich, St. Louis MO) and washed with PBS. Collected cells from the tumor and blood samples were placed in a staining solution containing 1% Bovine Serum Albumin (BSA; Sigma-Aldrich) and 1% CD16/CD32 Mouse BD Fc Block™ (BD Biosciences) in PBS. The following primary antibodies were used: Anti-human CD24 (APC) and anti-human/mouse CD44 (PE-Fluor 610) purchased from eBiosciences (San Diego, CA, USA). All cells from the blood were analyzed with a Galios Flow Cytometer (Beckman Coulter, Brea, CA, USA) running Kaluza software (Beckman Coulter). At least 5,000 events were analyzed and reported as the mean ± SEM.
Matossian M.D., Chang T., Wright M.K., Burks H.E., Elliott S., Sabol R.A., Wathieu H., Windsor G.O., Alzoubi M.S., King C.T., Bursavich J.B., Ham A.M., Savoie J.J., Nguyen K., Baddoo M., Flemington E., Sirenko O., Cromwell E.F., Hebert K.L., Lau F., Izadpanah R., Brown H., Sinha S., Zabaleta J., Riker A.I., Moroz K., Miele L., Zea A.H., Ochoa A., Bunnell B.A., Collins-Burow B.M., Martin E.C, & Burow M.E. (2021). In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types. Clinical & Translational Oncology, 24(1), 127-144.
+ Open protocol
+ Expand
4

Circulating Tumor Cell Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols
To analyze CSC phenotypes, TU-BcX-2O0 was enzymatically digested with type I collagenase (Worthington Biochemical Corporation, Lakewood, NJ, USA) at room temperature, neutralized with media, and then filtered. Circulating tumor cells were collected in whole blood with 0.5M EDTA (Gibco Invitrogen, Carlsbad CA, USA), incubated in red blood cell lysis buffer (0.008% NH4Cl, pH 7.2-7.4; Sigma-Aldrich, St. Louis MO, USA) and washed with PBS. Collected cells from the tumor and blood samples were placed in staining solution containing 1% Bovine Serum Albumin (BSA; Sigma- Aldrich) and 1% CD16/CD32 Mouse BD Fc BlockTM (BD Biosciences) in PBS. The following primary antibodies were used: Anti-human CD24 (APC), anti-human CD326 (EpCAM; PerCP-eFluor710) and anti-human/mouse CD44 (PE-Fluor 610) purchased from eBiosciences (San Diego, CA, USA). All cells from the blood were analyzed with a Galios Flow Cytometer (Beckman Coulter, Brea, CA, USA) running Kaluza software (Beckman Coulter). At least 5000 events were analyzed and reported as the mean ± SEM.
Matossian M.D., Burks H.E., Elliott S., Hoang V.T., Bowles A.C., Sabol R.A., Bunnell B.A., Martin E.C., Burow M.E, & Collins-Burow B.M. (2018). Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model. Oncoscience, 5(3-4), 99-108.
+ Open protocol
+ Expand
5

Circulating Tumor Cell Isolation and Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Circulating tumor cells were collected in whole blood with 0.5M EDTA (Gibco Invitrogen, Carlsbad CA), incubated in red blood cell lysis buffer (0.008% NH4Cl, pH 7.2–7.4; Sigma-Aldrich, St. Louis MO), and washed with PBS. Collected cells from the tumor and blood samples were placed in staining solution containing 1% Bovine Serum Albumin (BSA; Sigma-Aldrich) and 1% CD16/CD32 Mouse BD Fc BlockTM (BD Biosciences) in PBS. The following primary antibodies were used: Anti-human CD24 (APC), anti-human CD326 (EpCAM; PerCP-eFluor710) and anti-human/mouse CD44 (PE-Fluor 610) purchased from eBiosciences (San Diego, CA, USA). All cells from the blood were analyzed with a Galios Flow Cytometer (Beckman Coulter, Brea, CA, USA) running Kaluza software (Beckman Coulter). At least 5000 events were analyzed and reported as the mean ± SEM.
Matossian M.D., Burks H.E., Elliott S., Hoang V.T., Zuercher W.J., Wells C., Drewry D.H., Kapadia N., Chang T., Yan T., Windsor G., Nguyen K., Fang F., Nephew K., Buechlein A., Rusch D., Sabol R.A., Ucar D.A., Zabalta J., Miele L., Bunnell B.A., Collins-Burow B.M, & Burow M.E. (2020). A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple negative breast cancer to identify targetable signaling pathways. Anti-cancer drugs, 31(8), 759-775.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!